Survo

A 29-residue acylated synthetic peptide characterized in cell-based receptor-pharmacology and structural research.

Molecular Profile

Type
Synthetic peptide (acylated, 29 residues)
Molecular formula
C192H289N47O61
Molecular weight
~4,232 g/mol
CAS number
2805997-46-8
Amino acids
29
Fatty acid chain
C18 diacid
Modification
Position 2 substituted with Ac4c (1-aminocyclobutane-1-carboxylic acid); Lys-24 side chain acylated with an 18-carbon fatty diacid for albumin binding and extended half-life.

Mechanism & Target Class

Survo is a 29-residue synthetic peptide that engages class B G protein–coupled receptors. Its backbone carries substitutions including a non-natural amino acid at position 2 (Ac4c, 1-aminocyclobutane-1-carboxylic acid). An 18-carbon dicarboxylic acid covalently attached to the Lys-24 side chain confers reversible albumin binding, extending plasma half-life. These structural features — non-coded residues and fatty-acid acylation — are shared with other long-acting class B GPCR ligands studied in this research area.

Storage & Handling

Lyophilized
-20°C with desiccant; avoid repeated freeze–thaw; lyophilized form is stable for extended periods when properly stored and sealed.
Handling
Aliquoting minimizes freeze-thaw degradation; near-neutral pH buffers are suitable for solution stability; sterile conditions minimize oxidative and microbial exposure.

Primary Database

PubChem CID 168429725 ↗

References (20)

  1. Reviews

    1

    Winther JB, Holst JJ. (2024). Diabetes Obes Metab

    DOI: 10.1111/dom.15693PubMed 38853300

  2. 2

    Novikoff A, Müller TD. (2023). Peptides

    DOI: 10.1016/j.peptides.2023.171003PubMed 36997003

  3. 3

    Kajani S, Laker RC, Ratkova E, et al. (2024). Physiol Rev

    DOI: 10.1152/physrev.00028.2023PubMed 38300523

  4. 4

    Alfaris N, Waldrop S, Johnson V, et al. (2024). EClinicalMedicine

    DOI: 10.1016/j.eclinm.2024.102782PubMed 39281096

  5. 5

    Wen J, How-Volkman C, Truong A, et al. (2024). Cureus

    DOI: 10.7759/cureus.75304PubMed 39776746

  6. 6

    Yao Z, Wang C, Zhu Q, et al. (2023). Peptides

    DOI: 10.1016/j.peptides.2023.170955PubMed 36669563

  7. 7

    Li M, Hu J, Chin YH, et al. (2025). Front Endocrinol

    DOI: 10.3389/fendo.2025.1681965PubMed 41133230

  8. 8

    Mantovani A, Morandin R, Fiorio V, et al. (2025). Liver Int

    DOI: 10.1111/liv.70256PubMed 40736113

  9. 9

    Stachteas P, Nasoufidou A, Karakasis P, et al. (2025). Rev Cardiovasc Med

    DOI: 10.31083/RCM39691PubMed 40776973

  10. 10

    Zafer M, Tavaglione F, Romero-Gómez M, et al. (2025). Aliment Pharmacol Ther

    DOI: 10.1111/apt.70196PubMed 40364529

  11. Primary research

    11

    Le Roux CW, Steen O, Lucas KJ, et al. (2024). Lancet Diabetes Endocrinol

    DOI: 10.1016/S2213-8587(23)00356-XPubMed 38330987

  12. 12

    Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024). N Engl J Med

    DOI: 10.1056/NEJMoa2401755PubMed 38847460NCT04771273

  13. 13

    Sanyal AJ, Mazo DF, Younes R, et al. (2024). J Hepatol

    DOI: 10.1016/j.jhep.2024.06.003PubMed 38857788NCT05296733

  14. 14

    Thomas L, Martel E, Rist W, et al. (2024). Diabetes Obes Metab

    DOI: 10.1111/dom.15551PubMed 38560764

  15. 15

    Romero-Gómez M, Lawitz E, Shankar RR, et al. (2023). J Hepatol

    DOI: 10.1016/j.jhep.2023.06.009PubMed 37355043NCT04944992

  16. 16

    Zimmermann T, Thomas L, Baader-Pagler T, et al. (2022). Mol Metab

    DOI: 10.1016/j.molmet.2022.101633PubMed 36356832

  17. 17

    Li Y, Zhou Q, Dai A, et al. (2023). Proc Natl Acad Sci USA

    DOI: 10.1073/pnas.2303696120PubMed 37549266

  18. 18

    Corbin KD, Carnero EA, Allerton TD, et al. (2023). Obesity (Silver Spring)

    DOI: 10.1002/oby.23633PubMed 36695055

  19. 19

    Shankar SS, Daniels SJ, Robertson D, et al. (2024). Clin Gastroenterol Hepatol

    DOI: 10.1016/j.cgh.2024.04.017PubMed 38729399

  20. 20

    Zimmermann T, Bleymehl K, Haebel P, et al. (2026). Mol Metab

    DOI: 10.1016/j.molmet.2026.102326PubMed 41638399